Health Care • Medical Specialities
$21.68 ▲ +0.16
(+0.74%)
MKT CAP: $596.5M • VOL: 210.3K
52W L $13 52W H $31
FLGT // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $322.7M | $283.5M | $289.2M |
| YoY Revenue Growth % | +13.8% | -2.0% | — |
| Gross Profit | $130.9M | $107.2M | — |
| Gross Margin % | 40.6% | 37.8% | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$91.1M | -$73.9M | -$195.5M |
| Operating Margin % | -28.2% | -26.1% | -67.6% |
| Net Income (GAAP) | -$60.5M | -$42.7M | -$167.8M |
| EBITDA (Normalized) | -$73.0M | -$41.7M | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$101.6M | $21.1M | $27.0M |
| Capital Expenditures (CapEx) | $22.6M | $40.3M | — |
| Free Cash Flow (FCF) | -$124.2M | -$19.3M | $27.0M |
| FCF Margin % | -38.5% | -6.8% | 9.3% |
| Return on Invested Capital (ROIC %) | -6.8% | -5.4% | — |
| Cash & Short-Term Equivalents | $50.2M | $55.1M | — |
| Total Debt (Short + Long Term) | — | — | — |
| Total Stockholders' Equity | $1.11B | $1.13B | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR FLGT.